Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma

Table 1 Tumor-associated antigens detected in patients with hepatocellular carcinoma reported since 1993

Ref.	TAAs reported
Yau et al[36]	hnRNP L
Akada et al[42]	HSP70, SOD2, and PRDX6
Shao et al[41]	Glucose-regulated protein 78
Nomura et al[39]	Ku86
Liu et al[40]	CENPF, DDX3, HSPA4, HSPA5, VIM, LMNB1, and p53
Pekáriková et al[21]	CRT
Chen et al[28]	Sui1, RalA
Wang et al[43]	KRT23, AHSG and FTL
Wang et al[44]	RalA
Looi et al[45]	HSP60, HSP70
Li et al[35]	DDX3, eEF2, AIF, hnRNP A2, PBP, and TIM
Chen et al[46]	EIF3SI, LDHA, RFC2, and MCART1
Zhang et al[27]	IMP1, IMP2, IMP3, p53, c-myc, cyclin B1, survivin and p16
Akere et al[13]	p53
Zhou et al[47]	HCC-22-5
Takashima et al[48]	HSP70, GAPDH, PRX, Mn-SOD
Looi et al[49]	p16
Yagihashi et al[25]	Survivin
Su et al[17]	IMP2
Himoto et al[19]	IMPs
Himoto et al[18]	IMPs, p53, c-myc, and survivin
Zhang et al[24]	c-myc, cyclin B1, IMP1, Koc, p53, IMP2, and survivin
Soo Hoo et al[50]	p53, IMP2, Koc, CENP-F, p90
Le Naour et al[51]	CRT, CK8, NDK-A, and ATP5B
Zhang et al[23]	IMP2, CENPF
Zhang et al[20]	IMP2
Raedle et al[52]	p53
Covini et al[22]	Cyclin B1
Imai et al[53]	HCC1

TAAs: Tumor-associated antigens; HCC: Hepatocellular carcinoma; IMP: Insulin-like growth factor mRNA-binding; CENPF: Centromere protein F.